Evidence map›Paper›PMID 42266911›Full record

ReviewThe Lancet regional health. Europe2026

From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.

Camila A Picchio, Aina Nicolàs, Erika Duffell, Elisa Martró, Peter Vickerman, Sandra Dudareva, Sabela Lens, Axelle Vanderlinden, Joaquin Cabezas, Xavier Forns and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. A global commitment to addressing chronic liver disease.The Lancet regional health. Europe · 2026
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Camila A PicchioBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Aina NicolàsBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Erika DuffellEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Elisa MartróMicrobiology Department, Laboratori Clínic Metropolitana Nord, Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Barcelona, Spain.
Peter VickermanUniversity of Bristol, Bristol, United Kingdom.
Sandra DudarevaInstitute of Public Health, Riga Stradins University, Riga, Latvia.
Sabela LensLiver Unit, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Axelle VanderlindenViral Hepatitis Research Group Antwerp, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
Joaquin CabezasGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
Xavier FornsLiver Unit, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Upkar S GillCentre for Immunobiology & Infection, Blizard Institute, Barts and the London Faculty of Medicine & Dentistry, Queen Mary University of London, London, UK.
Devin Razavi-ShearerCDA Foundation, Lafayette, CO, USA.
Alessio AghemoDivision of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Rachel HalfordWorld Hepatitis Alliance, Geneva, Switzerland.
Thomas VanwolleghemViral Hepatitis Research Group Antwerp, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
Philippa C MatthewsThe Francis Crick Institute, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain public health threats in the WHO European region, where an estimated 29 million people live with chronic infection and viral hepatitis-related deaths now surpass those from HIV/AIDS and tuberculosis combined. Although effective prevention tools and antiviral treatments reduce the risk of complications, overall mortality has not declined. This Series paper reviews models of care (MoC) implemented between 2015 and 2025, drawing on scientific literature and policy documents to assess regional progress. Simplified testing and treatment, childhood and targeted adult HBV vaccination, harm-reduction programmes, and prison-based interventions have advanced elimination efforts. Pragmatic approaches, including point-of-care testing, decentralised services, and integrated models tailored to key populations demonstrate clear benefits. However, major challenges persist: large undiagnosed populations, regional disparities, inadequate healthcare worker knowledge, and inequities affect at-risk groups. Achieving elimination by 2030 will require accelerated case-finding, broader access to simplified treatment, stronger risk-tailored and vaccination strategies, improved data systems, and renewed commitment.

Indexed as

Disease eliminationHBV vaccinationInfectious disease controlLinkage to careModels of careMonitoringPreventionTesting

Identifiers

PMID42266911
PMCPMC13245531

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.